Lilly(Eli) & Company

NYSE: LLY
$795.67
-$0.61 (-0.1%)
Closing Price on December 24, 2024

LLY Articles

The top analyst upgrades, downgrades and other research calls from Tuesday include Amazon.com, Boeing, Chesapeake Energy, Eli Lilly, Gilead Sciences, Micron Thecnology, NVIDIA, Procter & Gamble...
The December 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Credit Suisse has put together a list of biopharma companies in its coverage universe that stand to make significant moves in 2018.
The top analyst upgrades, downgrades and other research calls from Friday include Cheniere, Cisco, Eli Lilly, Intel, Kroger, Nokia, Rite Aid, Roku, Teva Pharmaceuticals, Tyson Foods, Walgreens Boots...
The December 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks increased.
The November 30 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks was mixed.
The October 31 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks decreased.
The October 13 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Here are 13 featured spin-offs already underway and potential spin-offs that could be seen in 2017 and into 2018 that could radically change how Wall Street and Main Street evaluate companies ahead.
At least eight large biotech and pharma outfits are scheduled to report their latest earnings and revenues this coming week.
These four top companies all have data that could move the shares the rest of this year and into 2018. All have been around for years and will remain sector leaders for years to come.
With Eli Lilly making a huge headline investment in a cancer vaccine, 24/7 Wall St. wanted to look under the hood to see what this deal really entails.
The September 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The top analyst upgrades, downgrades and other research calls from Tuesday include Alphabet, Check Point Software, Chesapeake Energy, Chevron, Intel, MannKind, Schlumberger and Transocean.
The September 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.